We specialize in securities fraud and shareholder litigation. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes. Accessibility StatementSkip Navigation MILWAUKEE, Nov. 24, 2025 /PRNewswire/ -- Ademi & Fruchter LLP is investigating possible securities fraud claims against DexCom, Inc. (NASDAQ: DXCM). The investigation results from inaccurate statements DexCom made regarding its business operations and prospects. Click here to join our inv ...

Nov 24, 2025 9:20 AM Eastern Standard Time Freeport McMoRan Inc. (FCX) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - Robbins Geller Rudman & Dowd LLP Share SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Freeport-McMoRan Inc. (NYSE: FCX) publicly traded securities between February 15, 2022 and September 24, 2025, inclusive (the "Class Period†), have until January 12, 2026 to seek appointment ...

Accessibility StatementSkip Navigation WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statemen ...

Accessibility StatementSkip Navigation NEW YORK, Nov. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of James Hardie Industries plc. (NYSE: JHX). Shareholders who purchased shares of JHX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Emai ...

PHILADELPHIA, Nov. 24, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the "Class Period"). Accessibility StatementSkip Navigation Investor Deadline: Investors who purchased MoonLake securities during the Class Period may, no later than December 15, 2025, ...

Core Viewpoint - Stride, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements and non-compliance with legal requirements during the class period from October 22, 2024, to October 28, 2025 [1][3]. Allegations Against Stride - The lawsuit alleges that Stride inflated enrollment numbers by retaining "ghost students" and cut staffing costs by overloading teachers beyond statutory limits [3]. - Stride is accused of ignoring compliance requirements, including background checks and licensure laws, and failing to provide federally mandated special education services [3]. - The company allegedly suppressed whistleblowers who reported financial directives aimed at preserving profit margins by delaying hiring and denying services [3]. - Stride reportedly lost existing and potential enrollments due to these practices [3]. Impact of Legal Issues - A complaint filed by the Gallup-McKinley County Schools Board of Education against Stride on September 14, 2025, led to a nearly 12% drop in Stride's stock price [4]. - Following an announcement on October 28, 2025, regarding "poor customer experience" leading to higher withdrawal rates and an estimated loss of 10,000-15,000 enrollments, Stride's stock price fell more than 54% [5]. Class Action Process - Investors who purchased Stride securities during the class period can seek appointment as lead plaintiff in the lawsuit, representing the interests of the class [6]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect the ability to share in any potential recovery [6]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been recognized for securing significant monetary relief for investors, including the largest recovery in history of $7.2 billion in the Enron case [7].

CARMAX NOTICE: CarMax, Inc. (KMX) Faces Securities Fraud Allegations after Stock Drops 20%, Investors Urged to Contact BFA LawNovember 24, 2025 6:08 AM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 24, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against CarMax, Inc. (NYSE: KMX) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting f ...

MOONLAKE NOTICE: MoonLake Immunotherapeutics (MLTX) Faces Securities Fraud Allegations after Stock Drops 90%, Investors Urged to Contact BFA LawNovember 24, 2025 6:08 AM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 24, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal ...

STRIDE NOTICE: Stride, Inc. (LRN) Faces Securities Fraud Allegations after Stock Drops 50%, Investors Urged to Contact BFA LawNovember 24, 2025 6:08 AM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 24, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Stride, Inc. (NYSE: LRN) and certain of the Company's senior executives for securities fraud after significant stock drops resulting fr ...

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - Synopsys, Inc. provides design automation software products used for designing and testing integrated circuits. Its Design IP segment, which supplies pre-designed silicon components to semiconductor companies, has been the fastest-growing segment, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. Financial Performance - In Q3 2025, Synopsys reported a revenue of $425.9 million for its Design IP segment, reflecting a 7.7% decline year-over-year. The net income was $242.5 million, marking a 43% year-over-year decline [6]. Customer Dynamics - The lawsuit alleges that while Synopsys claimed its customers relied on its IP to minimize integration risk and speed time to market, the reality was that customers began requiring more customization for IP components, negatively impacting the economics of the Design IP business and threatening its business model [5]. Stock Market Reaction - Following the release of disappointing Q3 2025 results, Synopsys' stock price fell from $604.37 per share on September 9, 2025, to $387.78 per share on September 10, 2025, a decline of nearly 36% [6].